Merck inks $200 million deal for Hengrui's midstage heart disease drug
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Branded formulation business continues to perform well across domestic and export markets
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Subscribe To Our Newsletter & Stay Updated